Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | 0.24 |
| FCF Yield | 84.49% | -341.19% | -74.36% | 0.12% |
| EV / EBITDA | 5.10 | 3.58 | -0.22 | -94.12 |
| Quality | ||||
| ROIC | -29.42% | -40.50% | -34.82% | 11,233.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 63.50% |
| Cash Conversion Ratio | 1.23 | -0.61 | 1.38 | -0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -53.00% | -15.77% | -14.92% | -5.16% |
| Free Cash Flow Growth | 128.51% | -101.20% | -255.69% | 221.45% |
| Safety | ||||
| Net Debt / EBITDA | 6.13 | 4.07 | 1.15 | -0.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -54.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.20 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -281.23 |